Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Expenditures (2016 - 2025)

ImmunityBio (IBRX) has disclosed Capital Expenditures for 12 consecutive years, with $903000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 83.66% to $903000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.8 million, a 44.16% decrease, with the full-year FY2025 number at $3.8 million, down 44.16% from a year prior.
  • Capital Expenditures was $903000.0 for Q4 2025 at ImmunityBio, up from $741000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $45.8 million in Q3 2022 to a low of -$13.9 million in Q2 2022.
  • A 5-year average of $6.1 million and a median of $3.5 million in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1829.97% in 2021, then plummeted 272.69% in 2022.
  • ImmunityBio's Capital Expenditures stood at $10.4 million in 2021, then skyrocketed by 81.98% to $18.9 million in 2022, then crashed by 157.59% to -$10.9 million in 2023, then skyrocketed by 150.68% to $5.5 million in 2024, then tumbled by 83.66% to $903000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Capital Expenditures are $903000.0 (Q4 2025), $741000.0 (Q3 2025), and $1.1 million (Q2 2025).